Sophiris Bio Inc (NASDAQ:SPHS)’s share price fell 6% on Friday . The stock traded as low as $2.20 and last traded at $2.21. 764,794 shares changed hands during mid-day trading, an increase of 167% from the average session volume of 286,407 shares. The stock had previously closed at $2.35.

Several equities research analysts have commented on the stock. Maxim Group set a $6.00 target price on shares of Sophiris Bio and gave the company a “buy” rating in a research note on Monday. ValuEngine raised shares of Sophiris Bio from a “strong sell” rating to a “sell” rating in a research note on Friday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $6.00 target price on shares of Sophiris Bio in a research note on Friday, September 15th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $6.25.

The company has a debt-to-equity ratio of 0.60, a quick ratio of 13.37 and a current ratio of 13.37.

An institutional investor recently raised its position in Sophiris Bio stock. Vanguard Group Inc. raised its position in Sophiris Bio Inc (NASDAQ:SPHS) by 1.0% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 731,437 shares of the biopharmaceutical company’s stock after purchasing an additional 7,600 shares during the period. Vanguard Group Inc. owned approximately 2.43% of Sophiris Bio worth $1,609,000 as of its most recent filing with the SEC. 5.56% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This article was posted by Watch List News and is the property of of Watch List News. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at

Sophiris Bio Company Profile

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with Analyst Ratings Network's FREE daily email newsletter.